Figure 3.
Figure 3. LRP/CD91-mediated endocytosis of 125I-labeled Hx-heme and activated α2-macroglobulin (α2M*) in COS-1 cells. (A) Time course of cell-associated radioactivity and degradation (measured as increase in TCA-soluble radioactivity) in cells incubated with 125I-labeled Hx-heme. The inset shows Western blot of solubilized COS-1 cells with the monoclonal antibodies (refer to legend for Figure 1) against the LRP/CD91 subunits. (B) Time course of uptake and degradation of 125I-labeled Hx-heme in the presence of the lysosomal inhibitors chloroquine and leupeptin (both 300 μM). (C-D) Similar experiments as in panels A and B using receptor-binding (methylamine-activated) 125I-α2-macroglobulin (α2M*) as radioligand instead. All values, which represent the measured radioactivity in percentage of the added radioactivity, are the mean ± 1 SD of triplicate determinations. Each well containing 300 μL medium was incubated with 3000 cpm 125I-Hx-heme (∼0.5 ng).

LRP/CD91-mediated endocytosis of125I-labeled Hx-heme and activated α2-macroglobulin (α2M*) in COS-1 cells. (A) Time course of cell-associated radioactivity and degradation (measured as increase in TCA-soluble radioactivity) in cells incubated with 125I-labeled Hx-heme. The inset shows Western blot of solubilized COS-1 cells with the monoclonal antibodies (refer to legend for Figure 1) against the LRP/CD91 subunits. (B) Time course of uptake and degradation of 125I-labeled Hx-heme in the presence of the lysosomal inhibitors chloroquine and leupeptin (both 300 μM). (C-D) Similar experiments as in panels A and B using receptor-binding (methylamine-activated) 125I-α2-macroglobulin (α2M*) as radioligand instead. All values, which represent the measured radioactivity in percentage of the added radioactivity, are the mean ± 1 SD of triplicate determinations. Each well containing 300 μL medium was incubated with 3000 cpm 125I-Hx-heme (∼0.5 ng).

Close Modal

or Create an Account

Close Modal
Close Modal